


EXHIBIT

5



[Home](#) > [Investors](#) > [Pharma Pipeline](#) >

Company	Figures & Reports	Sustainability	Media	Investors
Divisions	Countries	Health	Diseases	Products
			R&D	Careers

Roche Pharma Pipeline Product Development

- [Mission & Goals](#)
- [IR Agenda](#)
- [Investor Updates](#)
- [Presentations & Events](#)
- [Pharma Pipeline](#)
- [Diagnostics Products](#)
- [Figures & Reports](#)
- [Share Information](#)
- [Bond Information](#)
- [Corporate Governance](#)
- [Annual General Meeting](#)
- [Company Background](#)
- [Document Centre](#)
- [Contacts](#)

Compound/ Generic name	Trade name/ Temp. name	Proj. type	Molecule type	Mechanism of action	Indication	Phase	Proj. Partner filing date
Haematology and Nephrology							
R744	Mircera / CERA	NME	therapeutic protein	continuous erythropoietin receptor activator	renal anemia	filed US / EU	Chugai
Oncology							
R340	Xeloda capecitabine	AI	small molecule	oral fluoropyrimidine	mCRC (1st line) combo	filed US / EU	Chugai
R340	Xeloda capecitabine	AI	small molecule	oral fluoropyrimidine	mCRC (2nd line) combo	filed US / EU	
R435	Avastin bevacizumab	AI	monoclonal antibody	anti- VEGF monoclonal antibody	NSCLC (1st line)	filed EU / Approved US	Genentech
R435	Avastin bevacizumab	AI	monoclonal antibody	anti- VEGF monoclonal antibody	mBC (1st line) combo taxol	filed US / approved EU	Genentech
R435	Avastin bevacizumab	AI	monoclonal antibody	anti- VEGF monoclonal antibody	mCRC (1st line) combo oxaliplatin	filed EU	Genentech
R435	Avastin bevacizumab	AI	monoclonal antibody	anti- VEGF monoclonal antibody	RCC	filed	Genentech
Participation Through Chugai							
AVS	Antevas nicaraven	NME	small molecule	radical scavenger	subarachnoid hemorrhage	filed Jp	
EPOCH	Epogin epoetin beta	AI	therapeutic protein	ESA	chemotherapy induced anemia	filed Jp	
SG-75	Sigmart nicorandil	AI	small molecule	agonist	acute heart failure	filed Jp	

Note: For competitive reasons, some projects may not have been identified in this document.

Legend:

AI Additional Indication

AMD	Age-related Macular Degeneration
ANCA	Antineutrophil Cytoplasmic Antibodies
APO2L/TRAIL	APO-2 Ligand / TNF-Related Apoptosis Inducing Ligand
BC	Breast Cancer
CETP	Cholesteryl-Ester-Transfer-Protein
CHD	Coronary Heart Disease
CLL	Chronic Lymphocytic Leukemia
CRC	Colorectal Cancer
DMARD	Disease-Modifying Anti-Rheumatic Drug
EGFR	Epidermal Growth Factor Receptor
EU	European Union
GLP-1	Glucagon-Like Peptid 1
GPCR	G-Protein Coupled Receptor
HER	Human Epidermal Growth Factor Receptor
IBS	Irritable Bowel Syndrome
mBC	Metastatic Breast Cancer
mCRC	Metastatic Colorectal Cancer
MS	Multiple Sclerosis
NL	Lupus Nephritis
NME	New Molecular Entity
NSCLC	Non-Small Cell Lung Cancer
PDE4	Phosphodiesterase Type 4
RA	Rheumatoid Arthritis
RCC	Renal Cell Carcinoma
SLE	Systemic Lupus Erythematodes
SoJIA	Systemic Onset of Juvenile Idiopathic arthritis
TNF	Tumor Necrosis Factor
US	United States
VEGF	Vascular Endothelial Growth Factor

 [print this page](#)

26.3.2004

© 1996-2007 F.Hoffmann-La Roche
[Ltd](#)

This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any valid legal process, regulation, registration or usage in the country of your origin.